Centrexion Therapeutics
↗Boston, Massachusetts, United States
Centrexion Therapeutics Corporation is a clinical-stage biopharmaceutical company founded in 2013 and headquartered in Boston, Massachusetts. The company specializes in developing novel, non-opioid, and non-addictive therapies to address unmet medical needs in chronic pain management and immunology. Centrexion is strategically building a diversified portfolio with powerful opportunities in two emerging categories: non-opioid pain relief and immunology, with a focus on differentiated medicines in indications with the highest unmet medical needs. The company maintains prestigious partnerships with major pharmaceutical and research organizations including Eli Lilly and Company, Boehringer Ingelheim, and the National Institutes of Health (NIH), focusing on high-value markets with significant unmet need.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Non-opioid pain therapeutics, Immunology and Inflammation
SIZE & FINANCIALS
Employees:1-50
Founded:2013
Ownership:private
Status:operating
FUNDING
Stage:Private
Total Raised:$65.7M
Investors:Plutus Investment Group, Hibiscus Capital Management, National Institutes of Health, Eli Lilly, Exome Asset Management, Lilly Ventures, Presidio Partners, InterWest Partners, Alta Partners
STOCK
Exchange:NASDAQ
Ticker:CNTX
PIPELINE
Stage:Phase 1-3
Lead Drug Stage:Phase 3
Modalities:Small molecule, Intra-articular injection, Capsaicinoid compounds, SSTR4 agonists, CCR2 antagonists, CB2 agonists
Trial Phases:Phase 1: 2 | Phase 2: 1 | Phase 3: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Eli Lilly and Company - Licensed CNTX-0290 (Mazisotine) for $47.5M upfront plus up to $950M in milestone and royalties (2019), Boehringer Ingelheim - Licensed CNTX-0290, CNTX-6970, and CNTX-6016 to Centrexion (2016), National Institutes of Health - Research collaboration
COMPETITION
Position:Emerging
Competitors:Flexion Therapeutics, Cara Therapeutics, Eliem Therapeutics, Eli Lilly and Company, Regeneron Pharmaceuticals, Acorda Therapeutics, Biogen, Novartis AG +7 more
LEADERSHIP
Key Executives:
Jeffrey B. Kindler - Chief Executive Officer
James N. Campbell, M.D. - President and Chief Scientific Officer
Mike Ward - Chief Financial Officer / Chief Operations Officer
Randall Stevens, M.D. - Chief Medical Officer
Jonathan Guerriero - Chief Development Operations Officer
Charles Oh, M.D. - Senior Vice President, Clinical and Medical
Sarah Kelly - Vice President, Corporate Development
Smital Shah - Acting Chief Business Officer
Scientific Founders:James N. Campbell, M.D.
Board Members:Sol Barer, Ph.D. (Chairman), Colin Hill (Board Member), Joseph R. Swedish (Board Member), Shawn Tomasello (Board Member)
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Centrexion Therapeutics. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.